Posted inCardiagtech

Does Health Insurance Cover Long-Term Weight Loss Programs?

No Comments

Obesity is a significant health concern affecting millions of people worldwide. It’s linked to a range of serious conditions, including heart disease, type 2 diabetes, and certain cancers, making effective weight management crucial for overall well-being. Long-term weight loss programs, encompassing dietary changes, exercise plans, and behavioral therapy, can be instrumental in helping individuals achieve and maintain a healthy weight. However, the question of whether health insurance covers these vital programs often arises, creating uncertainty and potential barriers for those seeking help. Understanding the extent to which health care insurance covers long-term weight loss programs is essential for individuals looking to invest in their health and navigate the complexities of healthcare coverage. This article delves into the landscape of insurance coverage for weight loss programs, exploring what is typically covered, what might be excluded, and how to determine the specifics of your own health plan.

Navigating Health Insurance Coverage for Weight Loss Programs

The landscape of health insurance coverage for weight loss programs can be intricate and vary significantly depending on numerous factors. While the need for long-term support in managing weight is increasingly recognized, insurance policies differ in their approach to covering these services. To effectively understand and utilize your health insurance benefits for weight loss, it’s crucial to examine several key aspects.

Understanding the Basics of Health Insurance and Weight Management

Before delving into the specifics of weight loss program coverage, it’s important to understand the general framework of health insurance and how it typically approaches preventative care and disease management. Most health insurance plans are designed to cover medically necessary services, which are treatments, procedures, or supplies needed to diagnose or treat a medical condition and that meet accepted standards of medical practice. In the context of weight management, this often means that coverage is more likely when weight loss is deemed medically necessary to treat or prevent obesity-related health conditions.

Preventive vs. Therapeutic Care: Health insurance often distinguishes between preventive care and therapeutic care. Preventive services, such as routine check-ups and screenings, are aimed at preventing illness or detecting it early when treatment is most effective. The Affordable Care Act (ACA) in the United States, for instance, mandates that many preventive services be covered without cost-sharing (like copays or deductibles). Therapeutic services, on the other hand, are treatments for existing conditions. Weight loss programs can sometimes fall into either category, depending on the individual’s health status and the program’s focus.

Medical Necessity and Obesity: For weight loss programs to be considered medically necessary, there often needs to be a documented diagnosis of obesity or overweight, frequently accompanied by other health risk factors or comorbidities like diabetes, hypertension, or heart disease. Insurance providers often have specific criteria based on Body Mass Index (BMI) and the presence of these related health issues. If weight loss is seen as purely for cosmetic reasons, it is less likely to be covered.

Types of Weight Loss Programs and Potential Insurance Coverage

Weight loss programs are diverse, ranging from self-directed diet and exercise plans to medically supervised programs involving healthcare professionals. Insurance coverage varies depending on the type of program and the services it includes. Here are some common types of weight loss programs and the likelihood of insurance coverage:

1. Medical Nutrition Therapy (MNT):

Medical Nutrition Therapy is often covered by health insurance, particularly when prescribed by a physician and provided by a Registered Dietitian Nutritionist (RDN). MNT involves an in-depth assessment of nutritional status, dietary counseling, and the development of a personalized eating plan to manage a medical condition. For individuals with obesity or obesity-related conditions like diabetes, MNT is frequently considered medically necessary.

  • Coverage Details: Many insurance plans, including Medicare and some private insurers, cover MNT for individuals diagnosed with diabetes or kidney disease. Coverage for obesity specifically can be more variable but is becoming increasingly common as obesity is recognized as a chronic disease. CPT codes 97802, 97803, and 97804, as listed in the original policy, are relevant to MNT and may be covered if selection criteria are met. HCPCS codes G0270 and G0271 also pertain to MNT reassessment and intervention and may be covered under similar conditions.

Alt text: A dietitian provides medical nutrition therapy to a patient, offering personalized dietary advice and assessment.

2. Behavioral Therapy and Counseling:

Behavioral therapy is a crucial component of long-term weight loss, addressing the psychological and emotional factors that contribute to eating habits and lifestyle choices. Counseling can be provided by psychologists, licensed clinical social workers, or other qualified healthcare professionals.

  • Coverage Details: Some insurance plans cover behavioral counseling for weight management, particularly when it’s part of a comprehensive weight loss program and deemed medically necessary. Coverage may be more likely if you have a diagnosed mental health condition that contributes to your eating habits or if counseling is prescribed as part of treatment for obesity-related comorbidities. However, coverage for stand-alone weight loss counseling may be less common than for MNT.

3. Weight Management Programs Supervised by Physicians:

Medically supervised weight loss programs often involve regular check-ins with a physician, along with nutritional counseling, exercise recommendations, and sometimes medication. These programs are typically designed for individuals with significant obesity or health risks.

  • Coverage Details: Coverage for physician-supervised programs varies greatly. Some plans may cover specific components of the program, such as office visits with the physician, certain lab tests, and potentially MNT if provided by an RDN within the practice. However, the overall program itself might not be fully covered. It’s essential to clarify which aspects of the program are considered eligible for reimbursement under your specific plan.

4. Commercial Weight Loss Programs:

Commercial programs like Weight Watchers (now WW), Jenny Craig, and Nutrisystem offer structured diet plans, support groups, and sometimes coaching. While these programs can be effective for some individuals, insurance coverage is generally limited.

  • Coverage Details: Typically, health insurance does not cover the costs of commercial weight loss programs directly. However, some employers or insurance plans may offer wellness programs that provide partial reimbursement or discounts for participating in these programs. These are often considered voluntary benefits and are not standard coverage.

5. Weight Loss Medications:

Prescription weight loss medications are sometimes used in conjunction with lifestyle modifications for individuals with obesity or overweight and related health conditions. Medications like Orlistat (Xenical, Alli), Liraglutide (Saxenda), Naltrexone-Bupropion (Contrave), and Phentermine-Topiramate (Qsymia) have been FDA-approved for chronic weight management, as discussed in the background section of the original policy.

  • Coverage Details: Coverage for weight loss medications is highly plan-dependent. Some insurance plans have specific formularies that include certain weight loss drugs, while others may exclude them entirely. Even when covered, there may be significant cost-sharing, such as high copays or coinsurance. It is crucial to check your plan’s formulary and any prior authorization requirements before starting medication. The original policy notes that many Aetna plans specifically exclude services and supplies related to obesity treatment, including weight reduction medications, so it is essential to verify plan-specific details.

6. Weight Loss Devices and Procedures:

Medical devices like Plenity, a device cleared by the FDA to aid in weight management, and procedures such as bariatric surgery are also options for weight loss.

  • Coverage Details: Coverage for weight loss devices and procedures is also variable. Plenity, as mentioned in the original article, is a relatively new device, and coverage is still evolving. Bariatric surgery, such as gastric bypass or sleeve gastrectomy, is more frequently covered by insurance when it is deemed medically necessary for individuals with severe obesity and related health conditions. However, even with bariatric surgery, there are often strict criteria that must be met, including BMI thresholds, documentation of failed attempts at non-surgical weight loss, and psychological evaluations. Pre-authorization is almost always required for bariatric surgery.

7. Exercise Programs and Gym Memberships:

Exercise is a cornerstone of weight management. However, direct insurance coverage for gym memberships or exercise programs is generally limited.

  • Coverage Details: Most health insurance plans do not cover gym memberships as a standard benefit. Some plans may offer wellness programs that include gym discounts or reimbursements for fitness-related expenses as part of broader wellness initiatives. Certain therapeutic exercise programs prescribed for specific medical conditions might be covered under physical therapy benefits, but these are typically not for general weight loss but rather for rehabilitation or treatment of injuries.

Factors Influencing Insurance Coverage Decisions

Several factors play a role in determining whether a specific weight loss program or service will be covered by your health insurance. Understanding these factors can help you navigate the process more effectively.

1. Type of Insurance Plan:

The type of health insurance plan you have significantly impacts your coverage. Common types of plans include:

  • Employer-Sponsored Plans: These plans are offered through your employer and can vary widely in coverage depending on the employer’s choices and negotiations with the insurance provider. Large employers may have more comprehensive wellness benefits.
  • Individual and Family Plans: Purchased directly from an insurance company or through the Health Insurance Marketplace (HealthCare.gov in the U.S.), these plans must adhere to ACA requirements, which include coverage for certain preventive services. However, the specific benefits can still vary by plan tier (Bronze, Silver, Gold, Platinum) and insurer.
  • Medicare: The federal health insurance program for people 65 or older, younger people with disabilities, and people with End-Stage Renal Disease. Medicare Part B covers MNT for diabetes and kidney disease and may cover obesity screening and counseling as preventive services. Medicare Advantage plans (Part C) may offer additional wellness benefits.
  • Medicaid: A joint federal and state program that provides health coverage to millions of Americans, including children, pregnant women, seniors, and people with disabilities. Medicaid coverage for weight loss programs varies by state, but many states offer MNT and some behavioral health services.

2. Specific Policy Language and Benefit Descriptions:

The exact wording of your insurance policy documents and benefit descriptions is crucial. Insurance policies are legal contracts, and the details of what is covered and excluded are outlined in these documents. Pay close attention to sections related to:

  • Preventive Services: Check for coverage of obesity screening, counseling, and MNT as preventive care.
  • Disease Management: Look for coverage related to the management of obesity and obesity-related comorbidities.
  • Exclusions: Be aware of any specific exclusions for weight loss programs, obesity treatment, or related services. As the original policy note indicates, many plans may have explicit exclusions.

3. Medical Necessity and Documentation:

Insurance companies typically require documentation of medical necessity to approve coverage for weight loss programs beyond basic preventive services. This often involves:

  • Physician Referral or Prescription: A referral from your primary care physician or a specialist can strengthen your case for coverage.
  • Diagnosis of Obesity or Overweight: Documentation of your BMI and weight-related health conditions is usually required.
  • Treatment Plan: A detailed plan outlining the weight loss program’s components, goals, and expected outcomes can be helpful.
  • Progress Notes: Regular documentation of your progress in the program, including weight loss, health improvements, and adherence to the plan, may be necessary to continue coverage.

4. State and Federal Regulations:

State and federal laws can influence insurance coverage. The ACA has expanded access to preventive services, but the implementation and interpretation of these provisions can vary. Some states may have specific mandates regarding obesity treatment coverage.

5. EEAT and Helpful Content Considerations for Insurance Coverage:

When seeking information and coverage for weight loss programs, Expertise, Experience, Authoritativeness, and Trustworthiness (EEAT) are important factors. For insurance providers, demonstrating EEAT in their coverage decisions involves:

  • Expertise: Relying on clinical guidelines and evidence-based practices in determining medical necessity and appropriate treatments for obesity.
  • Experience: Having a track record of effectively managing claims and providing coverage that aligns with patient needs and health outcomes.
  • Authoritativeness: Being recognized as a reputable and reliable source of health coverage information and decisions.
  • Trustworthiness: Operating transparently, providing clear policy language, and ensuring fair and consistent coverage decisions.

For individuals navigating insurance coverage, seeking information from authoritative sources like government health websites (e.g., HealthCare.gov, Medicare.gov), reputable medical organizations (e.g., American Heart Association, American Diabetes Association), and established insurance providers can enhance trust and understanding.

Steps to Determine Your Insurance Coverage for Weight Loss Programs

To effectively determine your specific insurance coverage for long-term weight loss programs, follow these steps:

1. Review Your Policy Documents:

Start by carefully reviewing your Summary of Benefits and Coverage (SBC) and your full policy documents. Look for sections on:

  • Preventive Care: Identify covered preventive services related to obesity.
  • Nutrition Counseling/MNT: Check for coverage of Medical Nutrition Therapy.
  • Behavioral Health Services: See if behavioral counseling for weight management is included.
  • Prescription Drug Formulary: Examine the list of covered medications to see if any weight loss drugs are included.
  • Exclusions: Carefully read the exclusions section to identify any specific exclusions related to weight loss or obesity treatment.

2. Contact Your Insurance Provider:

The most direct way to get accurate information is to contact your insurance provider directly. You can call the customer service number on your insurance card or use your insurer’s website or app to send a secure message. When you contact them, ask specific questions, such as:

  • “Does my plan cover long-term weight loss programs?”
  • “Is Medical Nutrition Therapy covered for obesity?”
  • “Are there any Registered Dietitian Nutritionists in my network who specialize in weight management?”
  • “Does my plan cover behavioral counseling for weight loss?”
  • “Are any prescription weight loss medications covered under my formulary?” If so, which ones and what are the cost-sharing amounts?
  • “Are there any specific criteria for coverage, such as BMI requirements or the presence of comorbidities?”
  • “Do I need prior authorization for any weight loss services or programs?”

3. Check Your Insurer’s Website and Provider Directory:

Many insurance providers have online resources that can be helpful:

  • Formulary Lookup: Use the formulary lookup tool on your insurer’s website to check medication coverage.
  • Provider Directory: Search for in-network Registered Dietitian Nutritionists, therapists, and physicians who specialize in weight management.
  • Coverage and Benefits Information: Look for FAQs, benefit summaries, and other resources that explain your coverage.

4. Talk to Your Doctor:

Discuss your weight loss goals with your primary care physician. They can:

  • Assess your medical necessity for weight loss programs.
  • Provide a referral to a Registered Dietitian Nutritionist or other specialists.
  • Help you understand the medical documentation needed for insurance approval.
  • Advise on appropriate weight loss programs and services based on your health status.

5. Appeal a Denial if Necessary:

If your insurance claim for a weight loss program or service is denied, you have the right to appeal. Understand the appeals process outlined by your insurer and be prepared to provide additional documentation of medical necessity, physician letters, and any other information that supports your case.

Conclusion: Empowering Your Weight Loss Journey with Insurance Knowledge

Navigating health insurance coverage for long-term weight loss programs requires diligence and proactive inquiry. While coverage is not always straightforward and can vary significantly, understanding your policy, asking the right questions, and working closely with your healthcare provider can maximize your access to covered services. Recognize that while some plans may have limitations or exclusions, there are often components of comprehensive weight loss programs, such as Medical Nutrition Therapy and behavioral counseling, that are frequently covered, especially when deemed medically necessary for managing obesity and related health conditions.

By taking the steps to understand your insurance benefits, you can make informed decisions about your weight loss journey, reduce financial barriers, and access the support you need to achieve lasting health improvements. Don’t hesitate to advocate for your health and utilize the resources available to you through your insurance plan to support your long-term weight management goals. Remember to always verify the specifics of your plan, as policies can change, and individual circumstances may affect coverage decisions. Taking charge of understanding your health insurance is a crucial step towards taking charge of your health and well-being.

References

The above policy is based on the following references:

  1. Abell TL, Minocha A, Abidi N. Looking to the future: Electrical stimulation for obesity. Am J Med Sci. 2006;331(4):226-232.
  2. American Gastroenterological Association medical position statement on obesity. Gastroenterology. 2002;123(3):879-881.
  3. American Obesity Association, C. Everett Koop Foundation, and Shape Up America! Guidance for treatment of adult obesity. Bethesda, MD: Shape Up America!; October 1996. Available at: http://www.shapeup.org/sua. Accessed March 16, 2000.
  4. American Society of Health-System Pharmacists, Inc. American Hospital Formulary Service Drug Information 98. Bethesda, MD: American Society of Health-System Pharmacists; 1998.
  5. Arena Pharmaceuticals. Belviq (lorcaserin hydrochloride) tablets, for oral use. Prescribing Information Zofingen, Switzerland: Arena; revised June 2012.
  6. Arterburn DE, DeLaet DE, Schauer DP. Obesity. In: BMJ Clinical Evidence. London, UK: BMJ Publishing Group; July 2005.
  7. Asp N G, Bjorntorp P, Britton M, et al. Obesity – problems and interventions. SBU Report No. 160. Stockholm, Sweden: Swedish Council on Technology Assessment in Health Care (SBU); 2002.
  8. Avenell A, Broom J, Brown TJ, et al. Systematic review of the long-term effects and economic consequences of treatments for obesity and implications for health improvement. Health Technol Assess. 2004;8(21): iii-iv, 1-182.
  9. Aventis Pharmaceuticals Inc. Tenuate (diethylpropion hydrochloride USP). Prescribing Information. Bridewater, NJ: Aventis; revised November 2003.
  10. Balazs A. Role of phytotherapy in the prevention and treatment of obesity. Orv Hetil. 2010;151(19):763-773.
  11. Ball SD, Altena TS. Comparison of the BOD POD and dual energy x-ray absorptiometry in men. Physiol Meas. 2004;25(3):671-678.
  12. Bjorntorp P. Treatment of obesity. Int J Obes Relat Metab Disord. 1992;16(suppl 3):S81-S84.
  13. Blissmer B, Riebe D, Dye G, et al. Health-related quality of life following a clinical weight loss intervention among overweight and obese adults: Intervention and 24 month follow-up effects. Health Qual Life Outcomes. 2006;4:43.
  14. Borel AL, Nazare JA, Smith J, et al. Improvement in insulin sensitivity following a 1-year lifestyle intervention program in viscerally obese men: Contribution of abdominal adiposity. Metabolism. 2012;61(2):262-72.
  15. Bra GA, Gray DS. Obesity. Part I. Pathogenesis. West J Med. 1988;149:429-441.
  16. Bray GA. Use and abuse of appetite-suppressant drugs in the treatment of obesity. Ann Intern Med. 1993;119(7 pt 2):707-713.
  17. Bruera E, Dev R. Palliative care: Assessment and management of anorexia and cachexia. UpToDate [serial online]. Waltham, MA: UpToDate; reviewed October 2013.
  18. Bueno NB, de Melo IV, Florêncio TT, Sawaya AL. Dietary medium-chain triacylglycerols versus long-chain triacylglycerols for body composition in adults: Systematic review and meta-analysis of randomized controlled trials. J Am Coll Nutr. 2015;34(2):175-183.
  19. Buffa R, Mereu E, Comandini O, et al. Bioelectrical impedance vector analysis (BIVA) for the assessment of two-compartment body composition. Eur J Clin Nutr. 2014;68(11):1234-1240.
  20. Cheatham SW, Stull KR, Fantigrassi M, Motel I. The efficacy of wearable activity tracking technology as part of a weight loss program: A systematic review. J Sports Med Phys Fitness. 2018;58(4):534-548.
  21. Cheplapharm. Xenical (orlistat) capsules, for oral use. Prescribing Information. Greifswald, Germany: Cheplapharm; revised 2017.
  22. Cho YK, Kim Y-J, Jung CH. Effect of sodium-glucose co-transporter 2 inhibitors on weight reduction in overweight and obese populations without diabetes: A systematic review and a meta-analysis. J Obes Metab Syndr. 2021;30(4):336-344.
  23. Croghan IT, Ebbert JO, Schroeder DR, et al. A randomized, open-label pilot of the combination of low-level laser therapy and lorcaserin for weight loss. BMC Obes. 2016;3:42.
  24. Dansinger ML, Tatsioni A, Wong JB, et al. Meta-analysis: The effect of dietary counseling for weight loss. Ann Intern Med. 2007;147(1):41-50.
  25. Day P. What is the evidence for the safety and effectiveness of surgical and non-surgical interventions for patients with morbid obesity? NZHTA Technical Brief Series. Christchurch, New Zealand: New Zealand Health Technology Assessment (NZHTA); 2005;4(1).
  26. de Miguel-Etayo P, Moreno LA, Iglesia I, et al. Body composition changes during interventions to treat overweight and obesity in children and adolescents: A descriptive review. Nutr Hosp. 2013;28(1):52-62.
  27. Dixon JB. Weight loss medications–where do they fit in? Aust Fam Physician. 2006;35(8):576-579.
  28. Echouffo Tcheugui JB, Ahima R. The CAMELLIA-TIMI 61 trial. Washington, DC: American College of Cardiology. July 24, 2019. Available at: https://www.acc.org/latest-in-cardiology/articles/2019/07/24/06/28/the-camellia-timi-61-trial. Accessed April 29, 2020.
  29. Eisai Inc. Belviq: FDA drug safety communication for Belviq. Tokyo, Japan; Eisai; 2020. Available at: https://www.belviq.com/. Accessed April 16, 2020.
  30. Farrin N, Rezazadeh L, Pourmoradian S, et al. Boron compound administration; a novel agent in weight management: A systematic review and meta-analysis of animal studies. J Trace Elem Med Biol. 2022;72:126969.
  31. Fioravante M, Alegre SM, Marin DM, et al. Weight loss and resting energy expenditure in patients with chronic hepatitis C before and during standard treatment. Nutrition. 2012;28(6):630-634.
  32. Foster DW. Gain and loss in weight. In: Harrison’s Principles of Internal Medicine. 14th ed. AS Fauci, E Braunwald, KJ Isselbacher, et al., eds. New York, NY: McGraw-Hill; 1998:244-246.
  33. Frankenfield D, Roth-Yousey L, Compher C. Comparison of predictive equations for resting metabolic rate in healthy nonobese and obese adults: A systematic review. J Am Diet Assoc. 2005;105(5):775-789.
  34. Garvey WT, Ryan DH, Look M, et al. Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): A randomized, placebo-controlled, phase 3 extension study. Am J Clin Nutr. 2012;95(2):297-308.
  35. Gelesis, Inc. Gelesis granted FDA clearance to market Plenity – a new prescription aid in weight management. Boston, MA: Gelesis; April 14, 2019a.
  36. Gelesis, Inc. Plenity, instructions for use. Boston, MA: Gelesis; 2019. Available at: https://www.gelesis.com/wp-content/uploads/DEN180060_Physician_IFU_FDA_FINAL_4.9.2019Gelesis.pdf. Accessed August 25, 2021.
  37. Gelesis, Inc. Study of Gelesis100 on body weight in overweight and obese subjects with and without type 2 diabetes. ClinicalTrials.gov Identifier: NCT02307279. Bethesda, MD: National Library of Medicine; updated September 11, 2019b.
  38. Genentech USA, Inc. Xenical (orlistat) capsules for oral use. Prescribing Information. South San Francisco, CA: Genentech USA; August 2015.
  39. Gibson AA, Seimon RV, Lee CM, et al. Do ketogenic diets really suppress appetite? A systematic review and meta-analysis. Obes Rev. 2015;16(1):64-76.
  40. GlaxoSmithKline (GSK). Alli (orlistat). Package Insert. Warren, NJ: GSK; revised April 2017.
  41. Goldberg LR, Heiss CJ, Parsons SD, et al. Hydration in older adults: The contribution of bioelectrical impedance analysis. Int J Speech Lang Pathol. 2014;16(3):273-281.
  42. Goldstein DJ, Potvin JH. Long-term weight loss: The effect of pharmacologic agents. Am J Clin Nutr. 1994;60(5):647-657.
  43. Haller C, Schwartz JB. Pharmacologic agents for weight reduction. J Gend Specif Med. 2002;5(5):16-21.
  44. Haverkort EB, Reijven PL, Binnekade JM, et al. Bioelectrical impedance analysis to estimate body composition in surgical and oncological patients: A systematic review. Eur J Clin Nutr. 2015;69(1):3-13.
  45. Henes ST, Johnson A, Toner M, et al. Assessing Resting Metabolic Rate in Overweight and Obese Adolescents With a Portable Indirect Calorimeter: A Pilot Study for Validation and Reliability. Nutr Clin Pract. 2016;31(3):355-361.
  46. Heshka S, Anderson JW, Atkinson RL, et al. Weight loss with self-help compared with a structured commercial program: A randomized trial. JAMA. 2003;289(14):1792-1798.
  47. Hobbins L, Hunter S, Gaoua N, Girard O. Normobaric hypoxic conditioning to maximize weight loss and ameliorate cardio-metabolic health in obese populations: A systematic review. Am J Physiol Regul Integr Comp Physiol. 2017;313(3):R251-R264.
  48. Institute for Clinical Systems Improvement (ICSI). Behavioral therapy programs for weight loss in adults. Technology Assessment Report No.87. Bloomington, MN: ICSI; January 2005.
  49. Institute for Clinical Systems Improvement (ICSI). Diet programs for weight loss in adults. Technology Assessment Report No. 83. Bloomington, MN: ICSI; August 2004. .
  50. Institute for Clinical Systems Improvement (ICSI). Treatment of obesity in children and adolescents. Technology Assessment Report No.90. Bloomington, MN: ICSI; 2005.
  51. Institute for Clinical Systems Improvement (ICSI). Pharmacological approaches to weight loss in adults. Technology Assessment Report No. 71. Bloomington, MN: ICSI; February 2003.
  52. Ioannides-Demos LL, Proietto J, Tonkin AM, McNeil JJ. Safety of drug therapies used for weight loss and treatment of obesity. Drug Saf. 2006;29(4):277-302.
  53. Jain A. What works for obesity? A summary of the research behind obesity interventions. London, UK: BMJ Publishing Group Ltd.; April 30, 2004.
  54. Jarvis M, McNaughton L, Seddon A, Thompson D. The acute 1-week effects of the Zone diet on body composition, blood lipid levels, and performance in recreational endurance athletes. J Strength Cond Res. 2002;16(1):50-57.
  55. Jensen MD, Ryan DH, Apovian CM, et al.; American College of Cardiology/American Heart Association Task Force on Practice Guidelines; Obesity Society. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society. Circulation. 2014;129(25 Suppl 2):S102-S138.
  56. Jo A, Coronel BD, Coakes CE, Mainous 3rd AG. Is there a benefit to patients using wearable devices such as Fitbit or health apps on mobiles? A systematic review. Am J Med. 2019;132(12):1394-1400.
  57. Khera R, Murad MH, Chandar AK, et al. Association of pharmacological treatments for obesity with weight loss and adverse events: A systematic review and meta-analysis. JAMA. 2016;315(22):2424-2434.
  58. Lambert M-L, Kohn L, Vinck I, et al. Pharmacological and surgical treatment of obesity. Residential care for severely obese children in Belgium. KCE Reports 36. Brussels, Belgium: Belgian Health Care Knowledge Centre (KCE); 2006.
  59. LeBlanc EL, Patnode CD, Webber EM, et al. Behavioral and pharmacotherapy weight loss interventions to prevent obesity-related morbidity and mortality in adults: An updated systematic review for the U.S. Preventive Services Task Force [Internet]. Agency for Healthcare Research and Quality: Rockville, MD. September 2018. Report No.: 18-05239-EF-1.
  60. Lee Y, Lee NY, Lim HJ, Sung S. Weight reduction interventions using digital health for employees with obesity: A systematic review. Diabetes Metab Syndr Obes. 2022;15:3121-3131.
  61. Li Z, Maglione M, Tu W, et al. Meta-analysis: Pharmacologic treatment of obesity. Ann Intern Med. 2005;142(7):532-546.
  62. Lingwood BE. Bioelectrical impedance analysis for assessment of fluid status and body composition in neonates — the good, the bad and the unknown. Eur J Clin Nutr. 2013;67 Suppl 1:S28-S33.
  63. Livingstone KM, Celis-Morales C, Lara J, et al. Associations between FTO genotype and total energy and macronutrient intake in adults: A systematic review and meta-analysis. Obes Rev. 2015;16(8):666-678.
  64. Livingstone KM, Celis-Morales C, Papandonatos GD, et al. FTO genotype and weight loss: Systematic review and meta-analysis of 9563 individual participant data from eight randomised controlled trials. BMJ. 2016;354:i4707.
  65. McDoniel SO, Nelson HA, Thomson CA. Employing RMR technology in a 90-day weight control program. Obes Facts. 2008;1(6):298-304.
  66. McTigue K M, Hess R, Ziouras J. Diagnosis and treatment of obesity in the elderly. Health Technology Assessment. Rockville, MD: Agency for Healthcare Research and Quality (AHRQ); December 18, 2003.
  67. McTigue K, Harris R, Hemphill MB, et al. Screening and interventions for overweight and obesity in adults. Preventive Services Task Force Systematic Evidence Review No. 21. Rockville, MD: Agency for Healthcare Research and Quality (AHRQ); 2003.
  68. Mosby-Year Book, Inc. Mosby’s GenRx: The Complete Reference for Generic and Brand Drugs. 8th ed. St. Louis, MO: Mosby; 1998.
  69. Mulholland Y, Nicokavoura E, Broom J, Rolland C. Very-low-energy diets and morbidity: A systematic review of longer-term evidence. Br J Nutr. 2012;108(5):832-851.
  70. Mumme K, Stonehouse W. Effects of medium-chain triglycerides on weight loss and body composition: A meta-analysis of randomized controlled trials. J Acad Nutr Diet. 2015;115(2):249-263.
  71. National Institute for Clinical Excellence (NICE). Guidance on the use of orlistat for the treatment of obesity in adults. Technology Appraisal Guidance No.22. London, UK: NICE; 2001.
  72. Nalpropion Pharmaceuticals, Inc. Contrave (naltrexone HCL and bupropion HCL) extended-release tablets. Prescribing Information. San Diego, CA: Nalpropion, revised April 2019.
  73. National Institute for Health and Care Excellence (NICE). Obesity: Identification, assessment and management of overweight and obesity in children, young people and adults. NICE Clinical Guidance No. 189. London, UK: NICE; November 2014.
  74. National Institute for Health and Clinical Excellence (NICE). Obesity: The prevention, identification, assessment and management of overweight and obesity in adults and children. Clinical Guideline 43. London, UK: NICE; 2006.
  75. National Task Force on the Prevention and Treatment of Obesity, National Institutes of Health. Very low-calorie diets. JAMA. 1993;270:967-974.
  76. National Task Force on the Prevention and Treatment of Obesity, National Institutes of Health. Long-term pharmacotherapy in the management of obesity.JAMA. 1996;276:1907-1915.
  77. NHS Centre for Reviews and Dissemination (CRD). The prevention and treatment of childhood obesity. Effective Health Care. York, UK: CRD; 2002; 7(6).
  78. No author listed. Metabolic drugs: Drugs used in obesity. In: AMA Drug Evaluations Subscription. DR Bennett, ed. Chicago, IL: American Medical Association (AMA); 1992: III/MET 6:7.
  79. No author listed. Weight control. In: Introductory Nutrition and Diet Therapy. 2nd ed. MM Eschleman, ed. Philadelphia, PA: J.B. Lippincott Co.;1991: 368.
  80. Novo Nordisk Inc. Novo Nordisk receives FDA approval for Saxenda (liraglutide [rDNA origin] injection) for chronic weight management. Press Relsease. Plainsboro, NJ: Novo Nordisk; December 24, 2014.
  81. Novo Nordisk Inc. Saxenda (liraglutide) injection, for subcutaneous use. Prescribing Information. Plainsboro, NJ: Novo Nordisk; revised March 2020.
  82. O’Meara S, Riemsma R, Shirran L, et al. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of orlistat in the management of obesity. Health Technol Assess. 2001;5(18):1-81.
  83. O’Meara S, Riemsma R, Shirran L, et al. A systematic review of the clinical effectiveness of orlistat used for the management of obesity. Obes Rev. 2004;5(1):51-68.
  84. O’Meara S, Riemsma R, Shirran L, et al. The clinical effectiveness and cost-effectiveness of sibutramine in the management of obesity: A technology assessment. Health Technol Assess. 2002;6(6):1-97.
  85. Onakpoya I, Hunt K, Wider B, Ernst E. Pyruvate supplementation for weight loss: A systematic review and meta-analysis of randomized clinical trials. Crit Rev Food Sci Nutr. 2014b;54(1):17-23.
  86. Onakpoya I, Posadzki P, Ernst E. The efficacy of glucomannan supplementation in overweight and obesity: A systematic review and meta-analysis of randomized clinical trials. J Am Coll Nutr. 2014a;33(1):70-78.
  87. Orexigen Therapeutics, Inc. Contrave (naltrexone HCL and bupropion HCL) extended-release tablets. Prescribing Information. La Jolla, CA: Orexigen; revised September 2014.
  88. Orozco LJ, Buchleitner AM, Gimenez-Perez G, et al. Exercise or exercise and diet for preventing type 2 diabetes mellitus. Cochrane Database Syst Rev. 2008;(3):CD003054.
  89. Padwal R, Li SK, Lau DC. Long-term pharmacotherapy for obesity and overweight. Cochrane Database Syst Rev. 2004;(3):CD004094.
  90. Paravattil B, Wilby KJ, Turgeon R. Topiramate monotherapy for weight reduction in patients with type 2 diabetes mellitus: A systematic review and meta-analysis. Diabetes Res Clin Pract. 2016;114:9-14.
  91. Pharmacia & Upjohn Company LLC. Didrex – benzphetamine hydrochloride tablet. Prescribing Information. New York, NY: Pfizer; revised March 2020.
  92. Pineau JC, Filliard JR, Bocquet M. Ultrasound techniques applied to body fat measurement in male and female athletes. J Athl Train. 2009;44(2):142-147.
  93. Pineau JC, Guihard-Costa AM, Bocquet M. Validation of ultrasound techniques applied to body fat measurement. A comparison between ultrasound techniques, air displacement plethysmography and bioelectrical impedance vs. dual-energy X-ray absorptiometry. Ann Nutr Metab. 2007;51(5):421-427.
  94. Pittler MH, Ernst E. Dietary supplements for body-weight reduction: A systematic review. Am J Clin Nutr. 2004;79(4):529-536.
  95. Primack C. A review and critique of published real-world weight management program studies. Postgrad Med. 2018;130(6):548-560.
  96. Rao S, Pandey A, Garg S, et al. Effect of exercise and pharmacological interventions on visceral adiposity: A systematic review and meta-analysis of long-term randomized controlled trials. Mayo Clin Proc. 2019;94(2):211-224.
  97. Ritz P, Sallé A, Audran M, Rohmer V. Comparison of different methods to assess body composition of weight loss in obese and diabetic patients. Diabetes Res Clin Pract. 2007;77(3):405-411.
  98. Rogovik AL, Chanoine JP, Goldman RD. Pharmacotherapy and weight-loss supplements for treatment of paediatric obesity. Drugs. 2010;70(3):335-346.
  99. Scheen AJ, Desaive C, Lefebvre PJ. Therapy for obesity–today and tomorrow. Baillieres Clin Endocrinol Metab. 1994;8(3):705-727.
  100. Shekelle P, Morton S, Maglione M. Ephedra and ephedrine for weight loss and athletic performance enhancement: Clinical efficacy and side effects. Evidence Report/Technology Assessment 76. Rockville, MD: Agency for Healthcare Research and Quality (AHRQ); 2003.
  101. Shekelle PG, Morton SC, Maglione MA, et al. Pharmacological and surgical treatment of obesity. Evidence Report/Technology Assessment No. 103. Prepared by the Southern California–RAND Evidence-Based Practice Center, Santa Monica, CA, under contract no. 290-02-0003. AHRQ Publication No. 04-E028-2. Rockville, MD: Agency for Healthcare Research and Quality; July 2004.
  102. Shepherd TM. Effective management of obesity. J Fam Pract. 2003;52(1):34-42.
  103. Silverstone T. Appetite suppressants: A review. Drugs. 1992;43(6):820-836.
  104. Smartt P. Evidence based review of weight loss medicines: A report commissioned by the New Zealand Accident Compensation Corporation (ACC). NZHTA Report. Christchurch, New Zealand: New Zealand Health Technology Assessment (NZHTA); 2004;7(6).
  105. Snow V, Barry P, Fitterman N, et al. Pharmacologic and surgical management of obesity in primary care: A clinical practice guideline from the American College of Physicians. Ann Intern Med. 2005:142(7):525-531.
  106. Stavrou S, Nicolaides NC, Papageorgiou I, et al. The effectiveness of a stress-management intervention program in the management of overweight and obesity in childhood and adolescence. J Mol Biochem. 2016;5(2):63-70.
  107. Swedish Council on Technology Assessment in Healthcare (SBU). Interventions to prevent obesity: A systematic review. Stockholm, Sweden; SBU; 2005.
  108. Talma H, Chinapaw MJ, Bakker B, et al. Bioelectrical impedance analysis to estimate body composition in children and adolescents: A systematic review and evidence appraisal of validity, responsiveness, reliability and measurement error. Obes Rev. 2013;14(11):895-905.
  109. Teva. Adipex-P (phentermine hydrochloride capsules USP). Package Insert. Horsham, PA: Teva; revised March 2017.
  110. Tsai AG, Wadden TA. Systematic review: An evaluation of major commercial weight loss programs in the United States. Ann Intern Med. 2005;142(1):56-66.
  111. U.S. Department of Agriculture and U.S. Department of Health and Human Services. Nutrition and your health: Dietary guidelines for Americans. 3rd ed. Home and Garden Bulletin. No. 232. Washington, DC: U.S. Government Printing Office; 1990.
  112. U.S. Department of Health and Human Services, National Institutes of Health (NIH). Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults. National Heart, Lung, and Blood Institute and National Institute of Diabetes and Digestive and Kidney Diseases. Bethesda, MD: NIH; June 1998.
  113. U.S. Food and Drug Administration (FDA), Center for Devices and Radiologic Health (CDRH). Letter to Gelesis, Inc. Re: Plenity (DEN180060). Silver Spring, MD: FDA; April 12, 2019.
  114. U.S. Food and Drug Administration (FDA). FDA approves weight-management drug Saxenda. Press Release. Silver Spring, MD: FDA; December 23, 2014.
  115. U.S. Food and Drug Administration (FDA). Meridia (sibutramine hydrochloride) information. Postmarketing drug safety information for patients and providers. Rockville, MD: FDA; updated October 8, 2010.
  116. U.S. Preventive Services Task Force. Behavioral counseling in primary care to promote physical activity: Recommendation and rationale. Ann Intern Med. 2002;137(3):205-207.
  117. U.S. Preventive Services Task Force. Behavioral counseling in primary care to promote a healthy diet: Recommendations and rationale. Am J Prev Med. 2003;24(1):93-100.
  118. U.S. Preventive Services Task Force. Screening for obesity in adults: Recommendations and rationale. Ann Intern Med. 2003;139(11):930-932.
  119. United States Pharmacopeial Convention, Inc. Appetite suppressants (systemic). In: USP DI: Drug Information for the Health Care Professional. 19th ed. Rockville, MD: United States Pharmacopeial Convention; 1999: 452-459.
  120. Virtus Pharmaceuticals, LLC. Phendimetrazine tartrate tablets, USP. Package Insert. Langhorne, PA: Virtus; revised June 2018.
  121. Vivus, Inc. Qsymia (phentermine and topiramate extended-release) capsules, for oral use. Prescribing Information. Campbell, CA: Vivus; revised March 2018.
  122. Wadden TA, Berkowitz RI, Womble LG, et al. Randomized trial of lifestyle modification and pharmacotherapy for obesity. N Engl J Med. 2005;353(20):2111-2120.
  123. Whiting S, Derbyshire EJ, Tiwari B. Could capsaicinoids help to support weight management? A systematic review and meta-analysis of energy intake data. Appetite. 2014;73:183-188.
  124. Whitlock EP, O’Connor EA, Williams SB, et al. Effectiveness of weight management programs in children and adolescents. Evidence Report/Technology Assessment No. 170. Prepared by the Oregon Evidence-based Practice Center under Contract No. 290-02-0024. AHRQ Publication No. 08-E014. Rockville, MD: Agency for Healthcare Research and Quality (AHRQ); September 2008.
  125. Whitlock EP, O’Connor EA, Williams SB, et al. Effectiveness of weight management interventions in children: A targeted systematic review for the USPSTF. Pediatrics. 2010;125(2):e396-e418.
  126. Whitlock EP, Williams SB, Gold R, et al. Screening and interventions for childhood overweight: A summary of evidence for the US Preventive Services Task Force. Pediatrics. 2005;116(1):e125-e144.
  127. Wilfley DE, Stein RI, Saelens BE, et al. Efficacy of maintenance treatment approaches for childhood overweight: A randomized controlled trial. JAMA. 2007;298(14):1661-1673.
  128. Williams JE, Wells JC, Wilson CM, et al. Evaluation of Lunar Prodigy dual-energy X-ray absorptiometry for assessing body composition in healthy persons and patients by comparison with the criterion 4-component model. Am J Clin Nutr. 2006;83(5):1047-1054.
  129. Wilms B, Schmid SM, Ernst B, et al. Poor prediction of resting energy expenditure in obese women by established equations. Metabolism. 2010;59(8):1181-1189.
  130. Xiang L, Wu H, Pan A, et al. FTO genotype and weight loss in diet and lifestyle interventions: A systematic review and meta-analysis. Am J Clin Nutr. 2016;103(4):1162-1170.
  131. Yanovski SZ, Yanovski JA. Long-term drug treatment for obesity: A systematic and clinical review. JAMA. 2014;311(1):74-86.

Comments

No comments yet. Why don’t you start the discussion?

Leave a Reply

Your email address will not be published. Required fields are marked *